Giuseppe Leone: This Review by Offidani’s Group Compares Clinical Trials and Outlines Prospects
LABORATORY Professionals International reposted Giuseppe Leone’s post on LinkedIn:
“At major international conferences in 2024, important data emerged on new approaches capable of improving outcomes even in high-risk or very advanced disease. Upfront quadruplet combinations, including anti-CD38 monoclonal antibodies, have proven to be the best therapy in terms of depth of response and long-term efficacy in both transplant-eligible and ineligible patients. Despite the introduction of these therapies, high-risk multiple myeloma (MM) remains challenging to treat. This review by Offidani’s group compares clinical trials and outlines prospects.”
Title: Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES
Authors: Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani
Read more here.
Stay updated with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh: Making Measurable Progress – Towards a World in Which No-one Ever Dies from Lack of a Vital Plasma-Derived Medicine
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation